BioPeople, Germany

Homberg leads Raupach’s novel Life Sciences Team

01.02.2010

Frankfurt – Raupach & Wollert-Elmendorff is expanding into the life sciences sector. In January, the respected German advisors for business law announced they had hired Peter Homberg as an Equity Partner. Homberg is a renowned expert for life sciences and intellectual property (IP). The specialist for transactions will head up the firm’s office in Frankfurt, which will especially address the needs of companies from the life sciences sector.
Homberg is arriving from Raupach’s competitor Jones Day, where he led the European Life Sciences team. He has a long track record in counseling companies from the pharma, biotech, diagnostics and medical devices branches. His colleague Andrea Veh has also moved to Raupach, and will work as an Associate in the new team.

Growth impulse

“For our Frankfurt office, Peter Hom­berg gives an important growth impulse,” said Martin Imbeck, Managing Partner at Raupach. Homberg said he is looking forward to establishing a new life sciences practice at the top-50 German-based law firm.
Up to now, Raupach has only provided counsel to firms in medical law. Hom­berg brings in additional expertise to accompany international financing rounds, M&As, licensing and patent deals – “From start-ups to large enterprises,” he says.
Homberg told EuroBiotechNews that he expects to quickly expand the new Life Sciences team. One possibility would be to admit additional patent attorneys.
Raupach ranks among the 50 largest German law firms, with more than 90 attorneys in seven offices throughout Germany, and an international network of partners. The company is a strategic partner of Deloitte, one of the leading international audit and consulting firms.
Before taking over his function at Jones Day, Hom­berg was Deputy General Counsel at Roche Diagnostics (formerly Boehringer Mannheim). Previously, he worked as Head of Equity Projects at a Daimler subsidiary, and also headed the Singapore office of Thümmel, Schütze & Partners. In 2000, Homberg joined Jones Day’s Frankfurt office, and from 2003 on he established Jones Day’s life sciences and IP practice in Munich.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/homberg-leads-raupachs-novel-life-sciences-team.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK71.7%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.3%
  • IMMUNICUM AB (S)16.60 SEK-36.2%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP756.4%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper